UNSPSC 51313103: Clocinizine

This classification denotes a histamine-1 receptor antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8HQJ711KH8. European Medicines Agency schedules Clocinizine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06685MIG. Clocinizine generally arises in the molecular formula C26H27CLN2. The term CLOCINIZINE is an International Non-Proprietary Name or INN. CLOCINIZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

Most nations schedule clocinizine under HS 29335995 and SITC 51576. As of Q4 2014, CLOCINIZINE remains the US FDA Preferred Term for this commodity. Clocinizine bears US NLM identifiers UMLS ID C1322002 and NCI Concept Code C77435. SMILES: CLC1CCC(C(N2CCN(CC2)C/C=C/C2CCCCC2)C2CCCCC2)CC1.

UNSPSC 51313103 Clocinizine is a Commodity code that covers pharmaceutical products, but the recent state and local activity posted under this code does not align with clocinizine procurement. Instead, Seminole County, Florida solicited naloxone and drug deactivation systems through an IFB, indicating that state and local governments tag emergency response and harm-reduction supplies under this pharmaceutical classification even when the specific product does not match the code's nominal scope. The work being solicited involves the supply and quarterly delivery of naloxone units and safe drug deactivation systems to support community health initiatives, with vendors responsible for all shipping and delivery costs included in their bids.

The recent activity is limited to a single known opportunity posted by a Florida county. Seminole County released IFB 60459723LAS on June 30, 2026, requesting 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023. The contract term is two years with a one-year renewal option, and vendors must meet standard compliance requirements including drug-free workplace certification, E-Verify authorization, and specified insurance coverages. The procurement is potentially FEMA-funded, introducing additional federal compliance obligations. The code shows minimal recent activity and appears to receive inconsistent tagging by state and local procurement offices for pharmaceutical and emergency-response supplies.